Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Meeting ReportGeneral Clinical Specialties

BI-847325 suppressed both wild and vemurafenib-resistant thyroid carcinoma BCPAP cells via inhibition of MEK/ERK pathway

Pengyi Deng and Bangping Cui
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 511;
Pengyi Deng
1Nuclear Medicine Yichang Central Peoples Hospital Yichang China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bangping Cui
1Nuclear Medicine Yichang Central Peoples Hospital Yichang China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

511

Objectives: To investigate the inhibitory effect of BI-847325, a novel MEK inhibitor, on the proliferation of BRAFV600E mutant thyroid carcinoma cell line BCPAP and the expression regulation of apoptotic proteins as well as sodium/iodide symporter (NIS).

Methods: BCPAP cells were treated for 48 h with different concentrations of BI-847325. The effect of BI-847325 on the proliferation of BCPAP cells was investigated by the CCK-8 assay; the apoptosis of BCPAP cells was evaluated by the flow cytometry; the activation level of MEK and its downstream apoptotic proteins and NIS were analyzed by Western Blotting. BCPAP cells were treated with 5 μM vemurafenib for 2 weeks to obtain vemurafenib-resistant BCPAP cells. The effect of BI-847325 on the proliferation of vemurafenib-resistant BCPAP cells was investigated by the CCK-8 assay, and the activation level of MEK was analyzed by Western Blotting.

Results: (1) BI-847325 inhibited the proliferation of BCPAP cells and the IC50 of BI-847325 for 48h was 0.46 μM. (2) BI-847325 induced apoptosis of BCPAP cells, and the apoptosis rate was (26.41±2.23)% when the concentration was 0.4 μM. (3) BI-847325 suppressed the activation level of MEK 1/2,ERK 1/2, and adjusted the expression of BIM, BAX and BCL-2. (4) BI-847325 up-regulated the expression of sodium/iodide symporter (NIS). (5) BI-847325 inhibited the proliferation of vemurafenib-resistant BCPAP cells and the IC50 of BI-847325 for 48 h was 0.55 μM. Furthermore, reactivated MEK/ERK were suppressed by BI-847325 in vemurafenib-resistant BCPAP cells.

Conclusions: BI-847325 induced the apoptosis of BCPAP and vemurafenib-resistant BCPAP cells by inhibiting the activation level of MEK/ERK; BI-847325 up-regulated the expression of NIS, which might increase the 131I uptake of BCPAP cells. BI-847325 might be a potential thyroid cancer targeted therapy drug. Key words: BI-847325, thyroid carcinoma, apoptosis, MEK/ERK, NIS

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 60, Issue supplement 1
May 1, 2019
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
BI-847325 suppressed both wild and vemurafenib-resistant thyroid carcinoma BCPAP cells via inhibition of MEK/ERK pathway
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
BI-847325 suppressed both wild and vemurafenib-resistant thyroid carcinoma BCPAP cells via inhibition of MEK/ERK pathway
Pengyi Deng, Bangping Cui
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 511;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
BI-847325 suppressed both wild and vemurafenib-resistant thyroid carcinoma BCPAP cells via inhibition of MEK/ERK pathway
Pengyi Deng, Bangping Cui
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 511;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

General Clinical Specialties

  • Can FDG PET/CT imaging have a role in clinical cases of Dermatomyositis?
  • The Potential Role of NaF-PET/CT in Monitoring CAD Development in Patients with Moderate-to-Severe Psoriasis
  • COMMON PEDIATRIC NUCLEAR MEDICINE IMAGING STUDIES: A COMPREHENSIVE REVIEW
Show more General Clinical Specialties

Thyroid and Para-Thyroid

  • 18F-FCH PET/CT for patients with uremic hyperparathyroidism
  • Tc-99m DTPA orbital SPECT/CT guided Selection for riamcinolone Acetonide Injection in Patients with Thyroid Associated Ophthalmopathy
  • PET imaging of phosphodiesterase 4 in brain and peripheral organs of McCune-Albright syndrome
Show more Thyroid and Para-Thyroid

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire